In a cohort of 414 patients with DLBCL treated with CHOP-based therapy (GSE10846), patients with high PLK4 mRNA levels presented a significantly lower survival rates, compared to those with low PLK4 expression (Fig. 5f). The gene discussed is PLK4; the disease is diffuse large B-cell lymphoma.